- Home
- VTAK vs GLMD Comparison
VTAK vs GLMD Comparison
Compare VTAK & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- GLMD
- Stock Information
- Founded
- VTAK 2002
- GLMD 2000
- Country
- VTAK United States
- GLMD Israel
- Employees
- VTAK N/A
- GLMD N/A
- Industry
- VTAK Medical/Dental Instruments
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- VTAK Health Care
- GLMD Health Care
- Exchange
- VTAK Nasdaq
- GLMD Nasdaq
- Market Cap
- VTAK 3.1M
- GLMD 3.0M
- IPO Year
- VTAK 2018
- GLMD 2014
- Fundamental
- Price
- VTAK $0.18
- GLMD $1.48
- Analyst Decision
- VTAK
- GLMD Hold
- Analyst Count
- VTAK 0
- GLMD 1
- Target Price
- VTAK N/A
- GLMD N/A
- AVG Volume (30 Days)
- VTAK 1.4M
- GLMD 1.7M
- Earning Date
- VTAK 05-14-2025
- GLMD 05-22-2025
- Dividend Yield
- VTAK N/A
- GLMD N/A
- EPS Growth
- VTAK N/A
- GLMD N/A
- EPS
- VTAK N/A
- GLMD N/A
- Revenue
- VTAK $481,000.00
- GLMD N/A
- Revenue This Year
- VTAK $822.86
- GLMD N/A
- Revenue Next Year
- VTAK $168.42
- GLMD N/A
- P/E Ratio
- VTAK N/A
- GLMD N/A
- Revenue Growth
- VTAK 9.57
- GLMD N/A
- 52 Week Low
- VTAK $0.16
- GLMD $1.15
- 52 Week High
- VTAK $8.40
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- VTAK 32.34
- GLMD 54.70
- Support Level
- VTAK $0.17
- GLMD $1.36
- Resistance Level
- VTAK $0.21
- GLMD $1.53
- Average True Range (ATR)
- VTAK 0.03
- GLMD 0.08
- MACD
- VTAK -0.01
- GLMD 0.03
- Stochastic Oscillator
- VTAK 13.76
- GLMD 85.87
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.